Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2017 Sep 30

PMID 28958576

Citations 6

Authors

Wenyong Tong

Chrissa A Dwyer

Bryan E Thacker

Charles A Glass

Jillian R Brown

Kristina Hamill

Kelley W Moremen

Stephane Sarrazin

Philip L S M Gordts

Lara E Dozier

Gentry N Patrick

Yitzhak Tor

Jeffrey D Esko

Affiliations

Soon will be listed here.

Abstract

Iduronidase (IDUA)-deficient mice accumulate glycosaminoglycans in cells and tissues and exhibit many of the same neuropathological symptoms of patients suffering from Mucopolysaccharidosis I. Intravenous enzyme-replacement therapy for Mucopolysaccharidosis I ameliorates glycosaminoglycan storage and many of the somatic aspects of the disease but fails to treat neurological symptoms due to poor transport across the blood-brain barrier. In this study, we examined the delivery of IDUA conjugated to guanidinoneomycin (GNeo), a molecular transporter. GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. GNeo conjugation also enhanced glycosaminoglycan clearance by intranasally delivered sulfamidase to the brain of sulfamidase-deficient mice, a model of Mucopolysaccharidosis IIIA. These findings suggest the general utility of the guanidinoglycoside-based delivery system for restoring missing lysosomal enzymes in the brain.

Citing Articles

Local Delivery Strategies for Peptides and Proteins into the CNS: Status Quo, Challenges, and Future Perspectives.

Yue W, Shen J Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375758 PMC: 10302941. DOI: 10.3390/ph16060810.

Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.

Critchley B, Gaspar H, Benedetti S Mol Ther. 2022; 31(3):657-675.

PMID: 36457248 PMC: 10014236. DOI: 10.1016/j.ymthe.2022.11.015.

A Historical Review of Brain Drug Delivery.

Pardridge W Pharmaceutics. 2022; 14(6).

PMID: 35745855 PMC: 9229021. DOI: 10.3390/pharmaceutics14061283.

Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities.

Zapolnik P, Pyrkosz A Int J Mol Sci. 2021; 22(11).

PMID: 34070997 PMC: 8197095. DOI: 10.3390/ijms22115490.

Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.

Nan H, Park C, Maeng S Biomed Res Int. 2020; 2020:2408402.

PMID: 33344633 PMC: 7732385. DOI: 10.1155/2020/2408402.

References

Inoue M, Tong W, Esko J, Tor Y . Aggregation-mediated macromolecular uptake by a molecular transporter. ACS Chem Biol. 2013; 8(7):1383-8. PMC: 3773245. DOI: 10.1021/cb400172h. View

Xia H, Mao Q, Davidson B . The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol. 2001; 19(7):640-4. DOI: 10.1038/90242. View

Zhao K, Neufeld E . Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells. Protein Expr Purif. 2000; 19(1):202-11. DOI: 10.1006/prep.2000.1230. View

Dix A, Fischer L, Sarrazin S, Redgate C, Esko J, Tor Y . Cooperative, heparan sulfate-dependent cellular uptake of dimeric guanidinoglycosides. Chembiochem. 2010; 11(16):2302-10. PMC: 2997625. DOI: 10.1002/cbic.201000399. View

Lochhead J, Thorne R . Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2011; 64(7):614-28. DOI: 10.1016/j.addr.2011.11.002. View

Hinderer C, Katz N, Louboutin J, Bell P, Yu H, Nayal M . Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice. Hum Gene Ther. 2016; 27(11):906-915. DOI: 10.1089/hum.2016.101. View

Bhaumik M, Muller V, Rozaklis T, Johnson L, Dobrenis K, Bhattacharyya R . A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology. 1999; 9(12):1389-96. DOI: 10.1093/glycob/9.12.1389. View

Lachmann R . Enzyme replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2011; 23(6):588-93. DOI: 10.1097/MOP.0b013e32834c20d9. View

Dwyer C, Scudder S, Lin Y, Dozier L, Phan D, Allen N . Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice. Sci Rep. 2017; 7:46576. PMC: 5394534. DOI: 10.1038/srep46576. View

10.

Wolf D, Hanson L, Aronovich E, Nan Z, Low W, Frey 2nd W . Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol Genet Metab. 2012; 106(1):131-4. DOI: 10.1016/j.ymgme.2012.02.006. View

11.

Stanford K, Bishop J, Foley E, Gonzales J, Niesman I, Witztum J . Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009; 119(11):3236-45. PMC: 2769193. DOI: 10.1172/JCI38251. View

12.

Meng Y, Sohar I, Sleat D, Richardson J, Reuhl K, Jenkins R . Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. Mol Ther. 2014; 22(3):547-553. PMC: 3944336. DOI: 10.1038/mt.2013.267. View

13.

Wang L, Fuster M, Sriramarao P, Esko J . Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 2005; 6(9):902-10. DOI: 10.1038/ni1233. View

14.

Wexselblatt E, Esko J, Tor Y . GNeosomes: Highly Lysosomotropic Nanoassemblies for Lysosomal Delivery. ACS Nano. 2015; 9(4):3961-8. DOI: 10.1021/nn507382n. View

15.

Orii K, Grubb J, Vogler C, Levy B, Tan Y, Markova K . Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther. 2005; 12(2):345-52. PMC: 2587041. DOI: 10.1016/j.ymthe.2005.02.031. View

16.

Boado R, Hui E, Lu J, Zhou Q, Pardridge W . Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm. 2011; 8(4):1342-50. DOI: 10.1021/mp200136x. View

17.

Sands M . A Hitchhiker's guide to the blood-brain barrier: in trans delivery of a therapeutic enzyme. Mol Ther. 2014; 22(3):483-484. PMC: 3944337. DOI: 10.1038/mt.2014.12. View

18.

Hamill K, Wexselblatt E, Tong W, Esko J, Tor Y . Delivery of an active lysosomal enzyme using GNeosomes. J Mater Chem B. 2020; 4(35):5794-5797. DOI: 10.1039/c6tb01387b. View

19.

Boelens J, Wynn R, OMeara A, Veys P, Bertrand Y, Souillet G . Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007; 40(3):225-33. PMC: 7094454. DOI: 10.1038/sj.bmt.1705718. View

20.

Vite C, Wang P, Patel R, Walton R, Walkley S, Sellers R . Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. Mol Genet Metab. 2011; 103(3):268-74. PMC: 3130519. DOI: 10.1016/j.ymgme.2011.03.011. View